Results 71 to 80 of about 17,623 (143)

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source

A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study

, 2019
A simple method for the simultaneous quantification of meropenem and the recently approved β-lactamase inhibitor, vaborbactam, in human plasma and renal replacement therapy effluent (RRTE) was developed and validated. This antibiotic combination protects
Sime, Fekade B., Lipman, Jeffrey, Parker, Suzanne L., Pandey, Saurabh, Wallis, Steven C., Roberts, Jason A.   +5 more
core   +1 more source

METHOD DEVELOPMENT AND VALIDATION FOR MEROPENEMAND VABORBACTAM BY RP-HPLC METHOD

, 2023
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in Tablet dosage form. Chromatogram was run through Inertsil ODS C185mm (4.6 x 250mm).
D.Vaishnavi, Dr V.Kiran Kumar
core   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

Journal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm, Laura Czerkster Antochevis, Cibele Massotti Magagnin, Beatriz Arns, Tarsila Vieceli, Dariane Castro Pereira, Larissa Lutz, Ândrea Celestino de Souza, Jéssica Nesello dos Santos, Rafaela Ramalho Guerra, Gregory S. Medeiros, Lucas Santoro, Diego R. Falci, Maria Helena Rigatto, Afonso Luís Barth, Andreza Francisco Martins, Alexandre Prehn Zavascki   +16 more
doaj   +1 more source

Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance

Interdisciplinary Perspectives on Infectious Diseases, Volume 2026, Issue 1, 2026.
Meropenem is a broad‐spectrum carbapenem antibiotic essential for treating serious infections including urinary tract infections, pneumonia, sepsis, and meningitis. This narrative review examines meropenem resistance trends and prescribing practices for severe infections in Pakistan highlighting how inappropriate use drives local antimicrobial ...
Nasim Akhtar, Ejaz Ahmed Khan, Summiya Nizamuddin, Sana Anwar, S. H. Waqar, Sarwat Faisal, Sarmad Iqbal, Divakar Sharma   +7 more
wiley   +1 more source

VALIDATION OF SIMPLE ISOCRATIC RP-UPLC METHOD FOR MEROPENEM AND VABORBACTAM DETERMINATION AND IT'S APPLICATION IN THE STUDY OF STRESS DEGRADATION

, 2018
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in tablet dosage form. Chromatogram was run through SB C8 100 x 3.0 mm, 1.8m.
Sudha Rani Bollimuntha 1 *, Kalyana Seela Kottapalli 2, Bhavya Manda 3
core   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

, 2017
We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistance phenotypes and carbapenemase genotypes.
Mariana Castanheira, Robert K. Flamm, Michael D. Huband, Rodrigo E. Mendes   +3 more
core   +1 more source

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 2

, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958), Amelie Bosphore (14549900), Antoine Roux (14549894), Eric Farfour (11021923), Corentine Alauzet (14549885), Lise Cremet (14549888), Louise Ruffier d’Epenoux (14549879), Sophie Moussalih (14549891), Marc Vasse (335648), Sylvie C de Verdiere (14549897), Stephane Corvec (14549903), Anaelle Muggeo (14549882)   +11 more
core   +1 more source

Meropenem/ vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]

, 2020
Introduction: infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs.
Tumbarello, Mario, Rossolini, Gm, Del Giacomo, Paola, Novelli, A   +3 more
core   +1 more source